TY - JOUR
T1 - Elevation of Nε-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis
AU - Yagmur, Eray
AU - Tacke, Frank
AU - Weiss, Claudia
AU - Lahme, Birgit
AU - Manns, Michael P.
AU - Kiefer, Paul
AU - Trautwein, Christian
AU - Gressner, Axel M.
N1 - Funding Information:
This work was supported by the German Research Foundation (DFG fellowship grant TA 434/1-1 to F.T.).
PY - 2006/1
Y1 - 2006/1
N2 - Objectives: Progression of liver fibrosis to cirrhosis is a dire consequence of chronic liver diseases (CLD). Nε-(carboxymethyl)lysine (CML)-modified advanced glycation end products (AGEs) in patients with CLD could reflect the degree of severity of the disease. Design and methods: In 110 patients with CLD and 124 healthy controls, CML serum levels and their diagnostic sensitivity and specificity were determined and compared to hyaluronan (HA). Results: Serum levels of CML were significantly affected by the stage of liver cirrhosis and were closely associated with liver function capacity. CML correlated positively with HA (r = 0.639, P < 0.0001). In ROC analysis, the diagnostic sensitivity and specificity in distinguishing healthy controls from liver disease patients for CML (AUC 0.908; 95%-CI 0.863-0.942, cut-off 640 ng/mL, sensitivity 74.5% and specificity 97.6%) resembled HA (AUC 0.948; 95%-CI 0.907-0.974; cut-off 50 ng/mL, sensitivity 80.7% and specificity 97.9%). The combination of CML and HA shows an AUC of 0.932; 95%-CI 0.888-0.962; sensitivity 82.6%; and specificity 95.8%. Conclusions: Our data suggest that serum levels of CML could provide a supplementary diagnostic marker for advanced stages of liver cirrhosis. However, the quality of interaction needs further investigation.
AB - Objectives: Progression of liver fibrosis to cirrhosis is a dire consequence of chronic liver diseases (CLD). Nε-(carboxymethyl)lysine (CML)-modified advanced glycation end products (AGEs) in patients with CLD could reflect the degree of severity of the disease. Design and methods: In 110 patients with CLD and 124 healthy controls, CML serum levels and their diagnostic sensitivity and specificity were determined and compared to hyaluronan (HA). Results: Serum levels of CML were significantly affected by the stage of liver cirrhosis and were closely associated with liver function capacity. CML correlated positively with HA (r = 0.639, P < 0.0001). In ROC analysis, the diagnostic sensitivity and specificity in distinguishing healthy controls from liver disease patients for CML (AUC 0.908; 95%-CI 0.863-0.942, cut-off 640 ng/mL, sensitivity 74.5% and specificity 97.6%) resembled HA (AUC 0.948; 95%-CI 0.907-0.974; cut-off 50 ng/mL, sensitivity 80.7% and specificity 97.9%). The combination of CML and HA shows an AUC of 0.932; 95%-CI 0.888-0.962; sensitivity 82.6%; and specificity 95.8%. Conclusions: Our data suggest that serum levels of CML could provide a supplementary diagnostic marker for advanced stages of liver cirrhosis. However, the quality of interaction needs further investigation.
KW - Advanced glycation end products
KW - Carboxymethyl(lysine)
KW - Chronic liver disease
KW - Hyaluronan
KW - Hyaluronic acid
KW - Liver cirrhosis
KW - Serum marker
UR - https://www.scopus.com/pages/publications/29344443061
U2 - 10.1016/j.clinbiochem.2005.07.016
DO - 10.1016/j.clinbiochem.2005.07.016
M3 - Article
C2 - 16321365
AN - SCOPUS:29344443061
SN - 0009-9120
VL - 39
SP - 39
EP - 45
JO - Clinical Biochemistry
JF - Clinical Biochemistry
IS - 1
ER -